These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39471018)

  • 1. BRAF and NRAS Mutations and the Association with Prognosis of Acral Lentiginous and Nodular Melanomas in Indonesia.
    Anwar SL; Ferronika P; Cahyono R; Sugandhi W; Pradana GD
    Asian Pac J Cancer Prev; 2024 Oct; 25(10):3525-3531. PubMed ID: 39471018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
    Dika E; Veronesi G; Altimari A; Riefolo M; Ravaioli GM; Piraccini BM; Lambertini M; Campione E; Gruppioni E; Fiorentino M; Melotti B; Ferracin M; Patrizi A
    Am J Clin Pathol; 2020 Apr; 153(5):664-671. PubMed ID: 32017841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.
    Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA
    Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia.
    Rinonce HT; Sastri DJ; Trisnawati F; Kameswari B; Ferronika P; Irianiwati
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1454. PubMed ID: 34110110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
    Kodali N; Bhattaru A; Blanchard I; Sharma Y; Lipner SR
    Melanoma Res; 2024 Oct; 34(5):419-428. PubMed ID: 38564430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan.
    Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY
    J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
    Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
    Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
    Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
    Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
    Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CCND1 alterations during the progression of cutaneous malignant melanoma.
    Vízkeleti L; Ecsedi S; Rákosy Z; Orosz A; Lázár V; Emri G; Koroknai V; Kiss T; Ádány R; Balázs M
    Tumour Biol; 2012 Dec; 33(6):2189-99. PubMed ID: 23001925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
    Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.